Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

BrainCool

0,52 SEK

+0,58 %

Mindre end 1K følgere

BRAIN

First North Stockholm

Medical Equipment & Services

Health Care

Oversigt
Finansielt overblik og estimater
Ejerskab
Investorkonsensus
Sammenligne
+0,58 %
-8,96 %
-43,16 %
-65,57 %
-60,68 %
-62,18 %
-67,08 %
-87,40 %
-70,57 %

BrainCool operates in the medical technology sector. The company develops products for medical cooling of the brain. The technology is developed as cooling pads that are applied to different parts of the patient's body, where the system controls body temperature. The products are used in the treatment of various serious conditions including stroke, cardiac arrest, as well as concussion and migraine. BrainCool was founded in 2010 and is headquartered in Lund.

Læs mere
Markedsværdi
175,68 mio. SEK
Aktieomsætning
30,56 t SEK
Omsætning
39,96 mio.
EBIT %
-105,58 %
P/E
-
Udbytteafkast, %
-
Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
11.2
2026

Årsrapport '25

Alle
Selskabsmeddelelser
ViserAlle indholdstyper
Selskabsmeddelelse1.12.2025, 14.53

BrainCool publishes information document regarding rights issue

BrainCool
Selskabsmeddelelse26.11.2025, 11.35

Communiqué from extraordinary general meeting in BrainCool

BrainCool
Selskabsmeddelelse24.10.2025, 06.05

NOTICE OF EXTRA GENERAL MEETING IN BRAINCOOL AB (PUBL)

BrainCool

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Selskabsmeddelelse24.10.2025, 06.00

BrainCool carries out a rights issue of approximately SEK 42 million which is fully covered by subscription undertakings and advances publication of Q3 report

BrainCool
Selskabsmeddelelse15.8.2025, 06.00

BrainCool AB (publ) - Financial Report for Q2 2025

BrainCool
Selskabsmeddelelse2.5.2025, 06.00

ZOLL® orders custom-built IQool Tabletops to accelerate sales

BrainCool
Selskabsmeddelelse25.2.2025, 07.00

BrainCool receives an order for 10 demo versions of BrainCool™ System from ZOLL®

BrainCool
Selskabsmeddelelse18.2.2025, 07.00

BrainCool receives orders for consumable products to a value of SEK 8 million

BrainCool
Selskabsmeddelelse11.2.2025, 07.00

BrainCool AB (publ) - Year End Report 2024

BrainCool
Selskabsmeddelelse4.2.2025, 07.00

BrainCool receives market approval for BrainCool™ System in Malaysia

BrainCool
Selskabsmeddelelse8.1.2025, 07.02

Karolinska expands PRINCESS 2 with BrainCool's product RhinoChill® System to additional countries, first patient outside of Sweden included

BrainCool
Selskabsmeddelelse20.12.2024, 07.25

BrainCool AB (publ) adds two centers to the COTTIS 2 clinical study of its cooling systems in stroke patients

BrainCool
Selskabsmeddelelse3.12.2024, 14.10

BrainCool appoints Jens Lindberg as new Chairman of the Board

BrainCool
Selskabsmeddelelse1.11.2024, 07.00

BrainCool AB (publ) - Financial Report for Q3 2024

BrainCool
Selskabsmeddelelse23.9.2024, 06.39

BrainCool AB (publ) cancels the loan agreement with EIB, as it is no longer appropriate for the company

BrainCool
Selskabsmeddelelse15.8.2024, 06.00

BrainCool AB (publ) - Financial Report for Q2 2024

BrainCool
Selskabsmeddelelse5.7.2024, 09.35

BrainCool AB (publ) – the first patient has been treated with RhinoChill® System in the pivotal COTTIS 2 study

BrainCool
Selskabsmeddelelse28.6.2024, 10.35

BrainCool AB (publ) – the first patient can now be enrolled in the pivotal COTTIS 2 study

BrainCool
Selskabsmeddelelse26.6.2024, 11.50

Braincool AB (publ): Bulletin from the annual general meeting

BrainCool
Pressemeddelelse18.6.2024, 09.13

BioStock: BrainCool's new CEO on his visions for the company

BrainCool
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.